The NRGO-002 trial (ChiCTR-IIR-16007769) was a multicenter, randomized, controlled, phase III study assessing the benefit of thoracic radiotherapy (TRT) on survival in patients with EGFR-mutated OMD-NSCLC treated with icotinib as first-line treatment. The gene discussed is EGFR; the disease is occult macular dystrophy.